Search

Your search keyword '"Vegh Z"' showing total 251 results
Start Over Author "Vegh Z"
251 results on '"Vegh Z"'

2. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort

Author

Vegh, Z., Burisch, J., Pedersen, N., Kaimakliotis, I., Duricova, D., Bortlik, M., Avnstrøm, S., Vinding, K. Kofod, Olsen, J., Nielsen, K.R., Katsanos, K.H., Tsianos, E.V., Lakatos, L., Schwartz, D., Odes, S., Lupinacci, G., De Padova, A., Jonaitis, L., Kupcinskas, L., Turcan, S., Tighineanu, O., Mihu, I., Barros, L.F., Magro, F., Lazar, D., Goldis, A., Fernandez, A., Hernandez, V., Niewiadomski, O., Bell, S., Langholz, E., Munkholm, P., and Lakatos, P.L.

Published
2014
Full Text
View/download PDF

3. Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study

Author

Burisch, J., Vegh, Z., Pedersen, N., Čuković-Čavka, S., Turk, N., Kaimakliotis, I., Duricova, D., Bortlik, M., Shonová, O., Thorsgaard, N., Krabbe, S., Andersen, V., Dahlerup, J.F., Kjeldsen, J., Salupere, R., Olsen, J., Nielsen, K.R., Manninen, P., Collin, P., Katsanos, K.H., Tsianos, E.V., Ladefoged, K., Ragnarsson, G., Björnsson, E., Bailey, Y., O'Morain, C., Schwartz, D., Odes, S., Politi, P., Santini, A., Kiudelis, G., Kupcinskas, L., Turcan, S., Magro, F., Barros, L., Lazar, D., Goldis, A., Nikulina, I., Belousova, E., Sanromán, L., Martinez-Ares, D., Almer, S., Zhulina, Y., Halfvarson, J., Arebi, N., Houston, Y., Sebastian, S., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2014
Full Text
View/download PDF

4. DOP019 Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohort

Author

Burisch, J, Andersen, V, Čuković-Čavka, S, Lakatos, P L, DʼInca, R, Magro, F, Arebi, N, Kievit, L, Kaimakliotis, I, Valpiani, D, Katsanos, K H, Vegh, Z, Dahlerup, J F, Fumery, M, Pedersen, N, Halfvarson, J, Belousova, E, Nielsen, K R, Turcan, S, Ellul, P, Kupcinskas, L, Oksanen, P, Duricova, D, Giannotta, M, Goldis, A, Hernandez, V, Salupere, R, Odes, S, Langholz, E, and Munkholm, P

Published
2018
Full Text
View/download PDF

7. P695 The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., DʼIncà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

8. P727 Change in Crohnʼs disease behavior in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., DʼIncà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

9. P694 Disease course during the first five years following diagnosis in a prospective European population-based inception cohort – the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, J., Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J.F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K.R., Giannotta, M., Oksanen, P., Katsanos, K.H., Vegh, Z., Ellul, P., Schwartz, D., Čuković-Čavka, S., DʼIncà, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P.L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

11. P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort

Author

Lovasz, B.D., Kurti, Z., Rutka, M., Vegh, Z., Gecse, K.B., Farkas, K., Banai, J., Bene, L., Golovics, P.A., Gonczi, L., Gasztonyi, B., Kristof, T., Lakatos, L., Miheller, P., Palatka, K., Patai, A., Papp, M., Salamon, A., Szamosi, T., Szepes, Z., Toth, G.T., Vincze, A., Szalay, B., Molnar, T., and Lakatos, P.L.

Published
2017
Full Text
View/download PDF

18. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

Author

Kiss, L. S., Szamosi, T., Molnar, T., Miheller, P., Lakatos, L., Vincze, A., Palatka, K., Barta, Z., Gasztonyi, B., Salamon, A., Horvath, G., Tóth, G. T., Farkas, K., Banai, J., Tulassay, Z., Nagy, F., Szenes, M., Veres, G., Lovasz, B. D., Vegh, Z., Golovics, P. A., Szathmari, M., Papp, M., and Lakatos, P. L.

Published
2011
Full Text
View/download PDF

19. Cost analysis in a prospective European population-based inception cohort : is there a cost-saving effect of biological therapy?

Author

Burisch, J., Vardi, H., Schwartz, D., Krznaric, Z., Lakatos, P. L., Fumery, M., Kupcinskas, L., Magro, F., Belousova, E., Oksanen, P., Arebi, N., Langholz, E., Turcan, S., D'Inca, R., Hernandez, V., Valpiani, D., Vegh, Z., Giannotta, M., Katsanos, K. H., Duricova, D., Nielsen, K. R., Kievit, H. A. L., Ellul, P., Salupere, R., Goldis, A., Kaimakliotis, I., Pedersen, N., Andersen, V., Halfvarson, Jonas, Sebastian, S., Dahlerup, J. F., Munkholm, P., Odes, S., Burisch, J., Vardi, H., Schwartz, D., Krznaric, Z., Lakatos, P. L., Fumery, M., Kupcinskas, L., Magro, F., Belousova, E., Oksanen, P., Arebi, N., Langholz, E., Turcan, S., D'Inca, R., Hernandez, V., Valpiani, D., Vegh, Z., Giannotta, M., Katsanos, K. H., Duricova, D., Nielsen, K. R., Kievit, H. A. L., Ellul, P., Salupere, R., Goldis, A., Kaimakliotis, I., Pedersen, N., Andersen, V., Halfvarson, Jonas, Sebastian, S., Dahlerup, J. F., Munkholm, P., and Odes, S.

Published
2019
Full Text
View/download PDF

20. Immunomodulators reduce the risk of surgery and hospitalisation in Crohn’s disease in a prospective European population-based inception cohort: the Epi-IBD cohort

Author

Burisch, J., Andersen, V., Cukovic-Cavka, S., Lakatos, P. L., D Inca, R., Magro, F., Arebi, N., Kievit, L., Kaimakliotis, I., Valpiani, D., Katsanos, K. H., Vegh, Z., Dahlerup, J. F., Fumery, M., Pedersen, N., Halfvarson, J., Belousova, E., Nielsen, K. R., Turcan, S., Ellul, P., Kupcinskas, L., Oksanen, P., Duricova, D., Giannotta, M., Goldis, A., Vicent Hernandez, Salupere, R., Odes, S., Langholz, E., and Munkholm, P.

Subjects
616.344-002-031.84 [udc], Crohn disease, diagnosis, therapy, Biological therapy, methods, Immunologic factors, therapeutic use, Cohort studies, Regression analysis, Europe
Abstract

Background: Immunomodulators have both been shown to improve the disease course in IBD patients: however, the literature remains inconsistent. The aim of the study was to investigate the impact of treatment with immunomodulators and biological therapy on disease course and prognosis of patients diagnosed with Crohn’s disease (CD) from diagnosis and during the first 5 years of follow-up. Methods: The Epi-IBD cohort is a prospective population-based cohort of 1289 unselected, uniformly diagnosed patients with IBD diagnosed in 2010 in centres from Western and Eastern European countries. Clinical data were captured prospectively throughout the follow-up period. Associations between primary endpoints (surgery and hospitalisation) and covariates were analysed by stepwise Cox regression analysis using the proportional hazards assumption. The use of immunomodulators and biologics were included as time-dependent variables with an initial lag time of 3 months and 2 months, respectively. Results: A total of 488 (38%) patients were diagnosed with CD and included in the study. Patient characteristics are shown in Table 1. Prevalence of treatments on any given day during follow-up is shown in Figure 1. In total, 107 CD patients (22%) had a resection, while 176 (36%) patients were hospitalised because of CD. Treatment with immunomodulators was associated with a reduced risk of surgery (HR: 0.4 CI95% 0.2–0.6) as well as needing hospitalisation (HR: 0.3 CI95% 0.2–0.5) (Figure 2), while biological therapy was not (HR: 0.8 (0.4–1.3) and HR: 0.7 (0.5–1.2)). Other factors included in the regression analusis are shown in Table 2 [...].

Published
2018

21. Natural disease course of inflammatory bowel disease unclassified in a prospective European population-based inception cohort-the Epi-IBD cohort

Author

Burisch, J., Ellul, P., Arebi, N., Kaimakliotis, I., D'Inca, R., Andersen, V., Belousova, E., Hernandez, V., Vegh, Z., Turcan, S., Magro, F., Kupcinskas, L., Halfvarson, Jonas, Lakatos, P. L., Duricova, D., Kievit, L., Goldis, A., Dahlerup, J. F., Oksanen, P., Cukovic-Cavka, S., Fumery, M., Odes, S., Nielsen, K. R., Valpiani, D., Pedersen, N., Giannotta, M., Salupere, R., Katsanos, K. H., Langholz, E., Munkholm, P., Burisch, J., Ellul, P., Arebi, N., Kaimakliotis, I., D'Inca, R., Andersen, V., Belousova, E., Hernandez, V., Vegh, Z., Turcan, S., Magro, F., Kupcinskas, L., Halfvarson, Jonas, Lakatos, P. L., Duricova, D., Kievit, L., Goldis, A., Dahlerup, J. F., Oksanen, P., Cukovic-Cavka, S., Fumery, M., Odes, S., Nielsen, K. R., Valpiani, D., Pedersen, N., Giannotta, M., Salupere, R., Katsanos, K. H., Langholz, E., and Munkholm, P.

Published
2018

22. Disease course during the first five years following diagnosis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., Munkholm, P., Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

23. Change in Crohn's disease behavior in a prospective European population-based inception cohort - the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., Munkholm, P., Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

24. The risk of proximal disease extension in patients with limited ulcerative colitis in a prospective European population-based inception cohort - the ECCO-EpiCom cohort

Author

Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., Munkholm, P., Burisch, J., Halfvarson, Jonas, Kupcinskas, L., Hernandez, V., Kaimakliotis, I., Valpiani, D., Pedersen, N., Duricova, D., Kievit, L., Dahlerup, J. F., Fumery, M., Salupere, R., Arebi, N., Nielsen, K. R., Giannotta, M., Oksanen, P., Katsanos, K. H., Vegh, Z., Ellul, P., Schwartz, D., Cukovic-Cavka, S., D'Inca, R., Turcan, S., Magro, F., Goldis, A., Langholz, E., Lakatos, P. L., and Munkholm, P.

Published
2017
Full Text
View/download PDF

26. Low hippocampal PI(4,5)P2 contributes to reduced cognition in old mice as a result of loss of MARCKS

Author

Trovò, L., Ahmed, T., Callaerts-Vegh, Z., Buzzi, A., Bagni, C., Chuah, Marinee, VandenDriessche, Thierry, D'hooge, R., Balschun, D., Dotti, C.g., Cell Biology and Histology, and Division of Gene Therapy & Regenerative Medicine

Subjects
cognition, MARCKS, Aging, mice, brain dysfunction, hippocampal PI(4,5)P2
Abstract

Cognitive and motor performances decline during aging. Although it is clear that such signs reflect synaptic compromise, the underlying mechanisms have not been defined. We found that the levels and activity of the synaptic plasticity modulators phosphatidylinositol-(4,5)-bisphosphate (PI(4,5)P2) and phospholipase C? (PLC?) were substantially reduced in hippocampal synaptic membranes from old mice. In addition, these membranes contained reduced levels of the PI(4,5)P2-clustering molecule myristoylated alanine-rich C kinase substrate (MARCKS). Consistent with a cause-effect relationship, raising MARCKS levels in the brain of old mice led to increased synaptic membrane clustering of PI(4,5)P2 and to PLC? activation. MARCKS overexpression in the hippocampus of old mice or intraventricular perfusion of MARCKS peptide resulted in enhanced long-term potentiation and improved memory. These results reveal one of the mechanisms involved in brain dysfunction during aging.

Published
2013

27. Improved spatial learning is associated with increased hippocampal but not prefrontal long-term potentiation in mGluR4 knockout mice

Author

Iscru E, Hannelore Goddyn, Ahmed T, Callaerts-Vegh Z, D'Hooge R, and Balschun D

Subjects
Mice, Inbred C57BL, Mice, Knockout, Mice, Memory, Long-Term, Memory, Short-Term, Long-Term Potentiation, Animals, Picrotoxin, Prefrontal Cortex, GABA-A Receptor Antagonists, Maze Learning, Receptors, Metabotropic Glutamate, CA1 Region, Hippocampal
Abstract

Although much information about metabotropic glutamate receptors (mGluRs) and their role in normal and pathologic brain function has been accumulated during the last decades, the role of group III mGluRs is still scarcely documented. Here, we examined mGluR4 knockout mice for types of behavior and synaptic plasticity that depend on either the hippocampus or the prefrontal cortex (PFC). We found improved spatial short- and long-term memory in the radial arm maze, which was accompanied by enhanced long-term potentiation (LTP) in hippocampal CA1 region. In contrast, LTP in the PFC was unchanged when compared with wild-type controls. Changes in paired-pulse facilitation that became overt in the presence of the GABAA antagonist picrotoxin indicated a function of mGluR4 in maintaining the excitation/inhibition balance, which is of crucial importance for information processing in the brain and the deterioration of these processes in neuropsychological disorders such as autism, epilepsy and schizophrenia.

Published
2012

28. Unchanged surgery and hospitalization rates in an East-West European inception cohort despite differences in use of biologicals-3-year follow-up of the ECCO-EpiCom cohort

Author

Burisch, J., Kaimakliotis, I., Duricova, D., Kievit, L., Dahlerup, J. F., Salupere, R., Nielsen, K. R., Manninen, P., Tsianos, E. V., Vegh, Z., Odes, S., D'Inca, R., Kupcinskas, L., Turcan, S., Magro, F., Goldis, A., Hernandez, V., Halfvarson, Jonas, Arebi, N., Langholz, E., Lakatos, P. L., Munkholm, P., EpiCom Northern Italy, Group author, Burisch, J., Kaimakliotis, I., Duricova, D., Kievit, L., Dahlerup, J. F., Salupere, R., Nielsen, K. R., Manninen, P., Tsianos, E. V., Vegh, Z., Odes, S., D'Inca, R., Kupcinskas, L., Turcan, S., Magro, F., Goldis, A., Hernandez, V., Halfvarson, Jonas, Arebi, N., Langholz, E., Lakatos, P. L., Munkholm, P., and EpiCom Northern Italy, Group author

Abstract

Note: D'Inca R., On behalf of the EpiCom Northern Italy, Florence, Forlì, and Padova, Italy

Published
2015
Full Text
View/download PDF

29. Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort

Author

Vegh, Z, Burisch, J, Pedersen, N., Kaimakliotis, I, Duricova, D, Bortlik, M, Vinding, K Kofod, Avnstrøm, S, Olsen, J., Nielsen, K R, Katsanos, K H, Tsianos, E V, Lakatos, L, Schwartz, D, Odes, S, D'Incà, R, Beltrami, M, Kiudelis, G, Kupcinskap, L, Jucov, A, Turcan, S, Barros, L F, Magro, F, Lazar, D, Goldis, A, de Castro, L, Hernandez, V, Niewiadomski, O, Bell, S, Langholz, E, Munkholm, P, Lakatos, P L, Vegh, Z, Burisch, J, Pedersen, N., Kaimakliotis, I, Duricova, D, Bortlik, M, Vinding, K Kofod, Avnstrøm, S, Olsen, J., Nielsen, K R, Katsanos, K H, Tsianos, E V, Lakatos, L, Schwartz, D, Odes, S, D'Incà, R, Beltrami, M, Kiudelis, G, Kupcinskap, L, Jucov, A, Turcan, S, Barros, L F, Magro, F, Lazar, D, Goldis, A, de Castro, L, Hernandez, V, Niewiadomski, O, Bell, S, Langholz, E, Munkholm, P, and Lakatos, P L

Abstract

Background and Aims: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis. Methods: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn’s disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients’ data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu]. Results: In CD, 36 [19%] Western Europe/Australian and 6 [9%] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53% vs 45%; p = 0.27]. Surgery was performed in 17 [24%] CD patients in Eastern Europe and 13 [7%] in Western Europe/Australia [p < 0.001, pLogRank = 0.001]. Of CD patients from Eastern Europe, 24 [34%] were hospitalized, and 39 [21%] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16% vs 16%; p = 0.93]. Conclusions: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/Australian centres., BACKGROUND AND AIMS: The ECCO-EpiCom study investigates the differences in the incidence and therapeutic management of inflammatory bowel diseases [IBD] between Eastern and Western Europe. The aim of this study was to analyse the differences in the disease phenotype, medical therapy, surgery, and hospitalization rates in the ECCO-EpiCom 2011 inception cohort during the first year after diagnosis.METHODS: Nine Western, five Eastern European centres and one Australian centre with 258 Crohn's disease [CD], 380 ulcerative colitis [UC] and 71 IBD unclassified [IBDU] patients [female/male: 326/383; mean age at diagnosis: 40.9 years, SD: 17.3 years] participated. Patients' data were registered and entered in the web-based ECCO-EpiCom database [www.epicom-ecco.eu].RESULTS: In CD, 36 [19%] Western Europe/Australian and 6 [9%] Eastern European patients received biological therapy [p = 0.04], but the immunosuppressive [IS] use was equal and high in these regions [Eastern Europe vs Western Europe/Australia: 53% vs 45%; p = 0.27]. Surgery was performed in 17 [24%] CD patients in Eastern Europe and 13 [7%] in Western Europe/Australia [p < 0.001, pLogRank = 0.001]. Of CD patients from Eastern Europe, 24 [34%] were hospitalized, and 39 [21%] from Western Europe/Australia, [p = 0.02, pLogRank = 0.01]. In UC, exposure to biologicals and colectomy rates were low and hospitalization rates did not differ between these regions during the 1-year follow-up period [16% vs 16%; p = 0.93].CONCLUSIONS: During the first year after diagnosis, surgery and hospitalization rates were significantly higher in CD patients in Eastern Europe compared with Western Europe/Australia, whereas significantly more CD patients were treated with biologicals in the Western Europe/Australian centres.

Published
2015

30. Health care and patients' education in a European inflammatory bowel disease inception cohort:An ECCO-EpiCom study

Author

Burisch, J, Vegh, Z, Pedersen, Natalia, Cuković-Čavka, S, Turk, N, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup, J F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, K R, Manninen, P, Collin, P, Katsanos, K H, Tsianos, E V, Ladefoged, K, Ragnarsson, G, Björnsson, E, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Politi, P, Santini, A, Kiudelis, G, Kupcinskas, L, Turcan, S, Magro, F, Barros, L, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Sanromán, L, Martinez-Ares, D, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Houston, Y, Sebastian, S, Langholz, E, Lakatos, P L, Munkholm, P, Burisch, J, Vegh, Z, Pedersen, Natalia, Cuković-Čavka, S, Turk, N, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup, J F, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, K R, Manninen, P, Collin, P, Katsanos, K H, Tsianos, E V, Ladefoged, K, Ragnarsson, G, Björnsson, E, Bailey, Y, O'Morain, C, Schwartz, D, Odes, S, Politi, P, Santini, A, Kiudelis, G, Kupcinskas, L, Turcan, S, Magro, F, Barros, L, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Sanromán, L, Martinez-Ares, D, Almer, S, Zhulina, Y, Halfvarson, J, Arebi, N, Houston, Y, Sebastian, S, Langholz, E, Lakatos, P L, and Munkholm, P

Abstract

BACKGROUND AND AIMS: The EpiCom study and inception cohort was initiated in 2010 in 31 centers from 14 Western and 8 Eastern European countries, covering a 10.1million person background population. Our aim was to investigate whether there is a difference between Eastern and Western Europe in health care and education of patients with inflammatory bowel disease (IBD).METHODS: A quality of care (QoC) questionnaire was developed in the EpiCom group consisting of 16 questions covering 5 items: time interval between the onset of symptoms and diagnosis, information, education, empathy and access to health care providers.RESULTS: Of 1,515 patients, 947 (217 east/730 west) answered the QoC questionnaire. Only 23% of all patients had knowledge about IBD before diagnosis. In Eastern Europe, significantly more patients searched out information about IBD themselves (77% vs. 68%, p<0.05), the main source was the Internet (92% vs. 88% p=0.23). In Western Europe, significantly more patients were educated by nurses (19% vs. 1%, p<0.05), while in Eastern Europe, gastroenterologists were easier to contact (80% vs. 68%, p<0.05).CONCLUSION: Health care differed significantly between Eastern and Western Europe in all items, but satisfaction rates were high in both geographic regions. Because of the low awareness and the rising incidence of IBD, general information should be the focus of patient organizations and medical societies. In Western Europe IBD nurses play a very important role in reducing the burden of patient management.

Published
2014

31. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia:Results of the 2011 ECCO-EpiCom inception cohort

Author

Vegh, Z, Burisch, J., Pedersen, N., Kaimakliotis, I, Duricova, D, Bortlik, M, Avnstrøm, S, Vinding, K Kofod, Olsen, J., Nielsen, K R, Katsanos, K H, Tsianos, E V, Lakatos, L, Schwartz, D, Odes, S, Lupinacci, G, De Padova, A, Jonaitis, L, Kupcinskas, L, Turcan, S, Tighineanu, O, Mihu, I, Barros, L F, Magro, F, Lazar, D, Goldis, A, Fernandez, A, Hernandez, V, Niewiadomski, O, Bell, S, Langholz, E, Munkholm, P, Lakatos, P L, Vegh, Z, Burisch, J., Pedersen, N., Kaimakliotis, I, Duricova, D, Bortlik, M, Avnstrøm, S, Vinding, K Kofod, Olsen, J., Nielsen, K R, Katsanos, K H, Tsianos, E V, Lakatos, L, Schwartz, D, Odes, S, Lupinacci, G, De Padova, A, Jonaitis, L, Kupcinskas, L, Turcan, S, Tighineanu, O, Mihu, I, Barros, L F, Magro, F, Lazar, D, Goldis, A, Fernandez, A, Hernandez, V, Niewiadomski, O, Bell, S, Langholz, E, Munkholm, P, and Lakatos, P L

Abstract

BACKGROUND AND AIMS: The aim of the present study was to validate the IBD (inflammatory bowel diseases) incidence reported in the 2010 ECCO-EpiCom (European Crohn's and Colitis Organization-Epidemiological Committee) inception cohort by including a second independent inception cohort from participating centers in 2011 and an Australian center to investigate whether there is a difference in the incidence of IBD between Eastern and Western European countries and Australia.METHODS: Fourteen centers from 5 Eastern and 9 Western European countries and one center from Australia participated in the ECCO-EpiCom 2011 inception cohort. Patients' data regarding disease type, socio-demographic factors, extraintestinal manifestations and therapy were entered into the Web-based EpiCom database, www.ecco-epicom.eu.RESULTS: A total of 711 adult patients were diagnosed during the inclusion year 2011, 178 (25%) from Eastern, 461 (65%) from Western Europe and 72 (10%) from Australia; 259 (37%) patients were diagnosed with Crohn's disease, 380 (53%) with ulcerative colitis and 72 (10%) with IBD unclassified. The mean annual incidence rate for IBD was 11.3/100,000 in Eastern Europe, 14.0/100,000 in Western Europe and 30.3/100,000 in Australia. Significantly more patients were diagnosed with complicated disease at diagnosis in Eastern Europe compared to Western Europe (43% vs. 27%, p=0.02).CONCLUSION: Incidence rates, disease phenotype and initial treatment characteristics in the 2011 ECCO-EpiCom cohort were not significantly different from that reported in the 2010 cohort.

Published
2014

33. P197 Is the tuberculin skin test alone accurate in moderate-to-severe BCG vaccinated patients with inflammatory bowel disease to test for latent tuberculosis?

Author

Golovics, P.A., primary, Szabo, A., additional, Mandel, M., additional, Gyurcsanyi, A., additional, Kristof, K., additional, Vegh, Z., additional, Mohas, A., additional, Szilagyi, B., additional, Kurti, Z., additional, Csako, B., additional, Kiss, L., additional, Lovasz, B., additional, Gecse, K., additional, and Lakatos, P., additional

Published
2014
Full Text
View/download PDF

35. P293 eHealth: Individualisation of MMX mesalamine treatment and optimization of disease course via a self-managed web-based solution in active ulcerative colitis

Author

Pedersen, N., primary, Burisch, J., additional, Martinsen, L., additional, Bennedsen, M., additional, Thielsen, P., additional, Bell, S., additional, Vegh, Z., additional, Haaber, A., additional, Duricova, D., additional, Jess, T., additional, Langholz, E., additional, and Munkholm, P., additional

Published
2014
Full Text
View/download PDF

36. DOP047 Is hospitalization predicting the disease course in UC? Prevalence and predictors of hospitalization and re-hospitalization in ulcerative colitis in a population-based inception cohort between 2000–2012

Author

Lovasz, B., primary, Mandel, M., additional, Golovics, P.A., additional, Szita, I., additional, Vegh, Z., additional, Kiss, L., additional, Horvath, A., additional, Pandur, T., additional, Balogh, M., additional, Mohas, A., additional, Szilagyi, B., additional, Lakatos, L., additional, and Lakatos, P., additional

Published
2014
Full Text
View/download PDF

38. DOP048 Is hospitalization predicting the disease course in Crohn's disease? Prevalence and predictors of hospitalization and re-hospitalization in Crohn's disease in a population based inception cohort between 2000–2012

Author

Golovics, P.A., primary, Mandel, M., additional, Lovasz, B., additional, Vegh, Z., additional, Szita, I., additional, Kiss, L., additional, Balogh, M., additional, Mohas, A., additional, Szilagyi, B., additional, Pandur, T., additional, Lakatos, L., additional, and Lakatos, P., additional

Published
2014
Full Text
View/download PDF

41. Spred1 is required for synaptic plasticity and hippocampus-dependent learning

Author

Denayer, E. (Ellen), Ahmed, T. (Tariq), Brems, H. (Hilde), Woerden, G.M. (Geeske) van, Borgesius, N.Z., Callaerts-Vegh, Z. (Zsuzsanna), Yoshimura, A. (Akihiko), Hartmann, D. (Dieter), Elgersma, Y. (Ype), D'Hooge, R. (Rudi), Legius, E. (Eric), Balschun, D. (Detlef), Denayer, E. (Ellen), Ahmed, T. (Tariq), Brems, H. (Hilde), Woerden, G.M. (Geeske) van, Borgesius, N.Z., Callaerts-Vegh, Z. (Zsuzsanna), Yoshimura, A. (Akihiko), Hartmann, D. (Dieter), Elgersma, Y. (Ype), D'Hooge, R. (Rudi), Legius, E. (Eric), and Balschun, D. (Detlef)

Abstract

Germline mutations in SPRED1, a negative regulator of Ras, have been described in a neurofibromatosis type 1 (NF1)-like syndrome (NFLS) that included learning difficulties in some affected individuals. NFLS belongs to the group of phenotypically overlapping neurocardio-facial-cutaneous syndromes that are all caused by germ line mutations in genes of the Ras/mitogen-activated protein kinase extracellular signal-regulated kinase (ERK) pathway and that present with some degree of learning difficulties or mental retardation. We investigated hippocampus-dependent learning and memory as well as synaptic plasticity in Spred1-/-mice, an animal model of this newly discovered human syndrome. Spred1-/-mice show decreased learning and memory performance in the Morris water maze and visual-discrimination T-maze, but normal basic neuromotor and sensory abilities. Electrophysiological recordings on brain slices from these animals identified defects in short- and long-term synaptic hippocampal plasticity, including a disequilibrium between long-term potentiation (LTP) and long-term depression in CA1 region. Biochemical analysis, 4 h after LTP induction, demonstrated increased ERK-phosphorylation in Spred1-/-slices compared with those of wild-type littermates. This indicates that deficits in hippocampusdependent learning and synaptic plasticity induced by SPRED1 deficiency are related to hyperactivation of the Ras/ERK pathway. Copyright

Published
2008
Full Text
View/download PDF

43. Risk of colorectal cancer in CD patients with colonic involvement and stenosing disease. 1977 - 2012. Results from a population-based study

Author

Lovasz, B, primary, Lakatos, L, additional, Golovics, P, additional, David, G, additional, Pandur, T, additional, Erdelyi, Z, additional, Mester, G, additional, Balogh, M, additional, Szita, I, additional, Molnar, C, additional, Komaromi, E, additional, Vegh, Z, additional, Mandel, M, additional, Kiss, L, additional, and Lakatos, P, additional

Published
2013
Full Text
View/download PDF

44. Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain

Author

Moechars, D. (Dieder), Weston, M.C. (Matthew), Leo, S. (Sandra), Callaerts-Vegh, Z. (Zsuzsanna), Goris, I. (Ilse), Daneels, R.F., Buist, A. (A.), Cik, M. (M.), Spek, P.J. (Peter) van der, Kass, R.S. (Robert), Meert, T. (Theo), D'Hooge, R. (Rudi), Rosenmund, C. (Christian), Hampson, R.M. (R. Mark), Moechars, D. (Dieder), Weston, M.C. (Matthew), Leo, S. (Sandra), Callaerts-Vegh, Z. (Zsuzsanna), Goris, I. (Ilse), Daneels, R.F., Buist, A. (A.), Cik, M. (M.), Spek, P.J. (Peter) van der, Kass, R.S. (Robert), Meert, T. (Theo), D'Hooge, R. (Rudi), Rosenmund, C. (Christian), and Hampson, R.M. (R. Mark)

Abstract

Uptake of L-glutamate into synaptic vesicles is mediated by vesicular glutamate transporters (VGLUTs). Three transporters (VGLUT1-VGLUT3) are expressed in the mammalian CNS, with partial overlapping expression patterns, and VGLUT2 is the most abundantly expressed paralog in the thalamus, midbrain, and brainstem. Previous studies have shown that VGLUT1 is necessary for glutamatergic transmission in the hippocampus, but the role of VGLUT2 in excitatory transmission is unexplored in glutamatergic neurons and in vivo. We examined the electrophysiological and behavioral consequences of loss of either one or both alleles of VGLUT2. We show that targeted delet

Published
2006
Full Text
View/download PDF

45. P307 Age at diagnosis 40-years is not an accurate predictor of disease outcome in patients with Crohn's disease

Author

Lovasz, B.D., primary, Lakatos, L., additional, Golovics, P.A., additional, Horvath, A., additional, Szita, I., additional, Pandur, T., additional, Mandel, M., additional, Vegh, Z., additional, Mester, G., additional, Balogh, M., additional, Molnar, C., additional, Komaromi, E., additional, Kiss, L.S., additional, and Lakatos, P., additional

Published
2013
Full Text
View/download PDF

48. P624 Risk of colorectal cancer in CD patients with colonic involvement and stenosing disease. Results from a population-based study

Author

Golovics, P.A., primary, Lakatos, L., additional, Lovasz, B.D., additional, David, G., additional, Pandur, T., additional, Erdelyi, Z., additional, Mester, G., additional, Balogh, M., additional, Szita, I., additional, Molnar, C., additional, Komaromi, E., additional, Vegh, Z., additional, Mandel, M., additional, Kiss, L.S., additional, and Lakatos, P., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results